451 related articles for article (PubMed ID: 32092060)
1. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
[TBL] [Abstract][Full Text] [Related]
2. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
[TBL] [Abstract][Full Text] [Related]
3. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
[TBL] [Abstract][Full Text] [Related]
4. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
Moodie Z; Andersen-Nissen E; Grunenberg N; Dintwe OB; Omar FL; Kee JJ; Bekker LG; Laher F; Naicker N; Jani I; Mgodi NM; Hunidzarira P; Sebe M; Miner MD; Polakowski L; Ramirez S; Nebergall M; Takuva S; Sikhosana L; Heptinstall J; Seaton KE; De Rosa S; Diazgranados CA; Koutsoukos M; Van Der Meeren O; Barnett SW; Kanesa-Thasan N; Kublin JG; Tomaras GD; McElrath MJ; Corey L; Mngadi K; Goepfert P;
PLoS Med; 2024 Mar; 21(3):e1004360. PubMed ID: 38502656
[TBL] [Abstract][Full Text] [Related]
6. Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.
Zhao LP; Fiore-Gartland A; Carpp LN; Cohen KW; Rouphael N; Fleurs L; Dintwe O; Zhao M; Moodie Z; Fong Y; Garrett N; Huang Y; Innes C; Janes HE; Lazarus E; Michael NL; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; De Rosa SC; Corey L; Gray GE; Seaton KE; Yates NL; McElrath MJ; Frahm N; Tomaras GD; Gilbert PB
PLoS One; 2020; 15(1):e0226803. PubMed ID: 31999736
[TBL] [Abstract][Full Text] [Related]
7. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
[TBL] [Abstract][Full Text] [Related]
8. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.
Gray GE; Huang Y; Grunenberg N; Laher F; Roux S; Andersen-Nissen E; De Rosa SC; Flach B; Randhawa AK; Jensen R; Swann EM; Bekker LG; Innes C; Lazarus E; Morris L; Mkhize NN; Ferrari G; Montefiori DC; Shen X; Sawant S; Yates N; Hural J; Isaacs A; Phogat S; DiazGranados CA; Lee C; Sinangil F; Michael NL; Robb ML; Kublin JG; Gilbert PB; McElrath MJ; Tomaras GD; Corey L
Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534016
[TBL] [Abstract][Full Text] [Related]
9. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.
Gray GE; Bekker LG; Laher F; Malahleha M; Allen M; Moodie Z; Grunenberg N; Huang Y; Grove D; Prigmore B; Kee JJ; Benkeser D; Hural J; Innes C; Lazarus E; Meintjes G; Naicker N; Kalonji D; Nchabeleng M; Sebe M; Singh N; Kotze P; Kassim S; Dubula T; Naicker V; Brumskine W; Ncayiya CN; Ward AM; Garrett N; Kistnasami G; Gaffoor Z; Selepe P; Makhoba PB; Mathebula MP; Mda P; Adonis T; Mapetla KS; Modibedi B; Philip T; Kobane G; Bentley C; Ramirez S; Takuva S; Jones M; Sikhosana M; Atujuna M; Andrasik M; Hejazi NS; Puren A; Wiesner L; Phogat S; Diaz Granados C; Koutsoukos M; Van Der Meeren O; Barnett SW; Kanesa-Thasan N; Kublin JG; McElrath MJ; Gilbert PB; Janes H; Corey L;
N Engl J Med; 2021 Mar; 384(12):1089-1100. PubMed ID: 33761206
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.
Moodie Z; Dintwe O; Sawant S; Grove D; Huang Y; Janes H; Heptinstall J; Omar FL; Cohen K; De Rosa SC; Zhang L; Yates NL; Sarzotti-Kelsoe M; Seaton KE; Laher F; Bekker LG; Malahleha M; Innes C; Kassim S; Naicker N; Govender V; Sebe M; Singh N; Kotze P; Lazarus E; Nchabeleng M; Ward AM; Brumskine W; Dubula T; Randhawa AK; Grunenberg N; Hural J; Kee JJ; Benkeser D; Jin Y; Carpp LN; Allen M; D'Souza P; Tartaglia J; DiazGranados CA; Koutsoukos M; Gilbert PB; Kublin JG; Corey L; Andersen-Nissen E; Gray GE; Tomaras GD; McElrath MJ
J Infect Dis; 2022 Aug; 226(2):246-257. PubMed ID: 35758878
[TBL] [Abstract][Full Text] [Related]
11. Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120.
Chirenje ZM; Laher F; Dintwe O; Muyoyeta M; deCamp AC; He Z; Grunenberg N; Laher Omar F; Seaton KE; Polakowski L; Woodward Davis AS; Maganga L; Baden LR; Mayer K; Kalams S; Keefer M; Edupuganti S; Rodriguez B; Frank I; Scott H; Stranix-Chibanda L; Gurunathan S; Koutsoukos M; Van Der Meeren O; DiazGranados CA; Paez C; Andersen-Nissen E; Kublin J; Corey L; Ferrari G; Tomaras G; McElrath MJ;
J Infect Dis; 2023 Oct; ():. PubMed ID: 37795976
[TBL] [Abstract][Full Text] [Related]
12. DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial.
Rouphael NG; Morgan C; Li SS; Jensen R; Sanchez B; Karuna S; Swann E; Sobieszczyk ME; Frank I; Wilson GJ; Tieu HV; Maenza J; Norwood A; Kobie J; Sinangil F; Pantaleo G; Ding S; McElrath MJ; De Rosa SC; Montefiori DC; Ferrari G; Tomaras GD; Keefer MC;
J Clin Invest; 2019 Nov; 129(11):4769-4785. PubMed ID: 31566579
[TBL] [Abstract][Full Text] [Related]
13. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.
Pantaleo G; Janes H; Karuna S; Grant S; Ouedraogo GL; Allen M; Tomaras GD; Frahm N; Montefiori DC; Ferrari G; Ding S; Lee C; Robb ML; Esteban M; Wagner R; Bart PA; Rettby N; McElrath MJ; Gilbert PB; Kublin JG; Corey L;
Lancet HIV; 2019 Nov; 6(11):e737-e749. PubMed ID: 31601541
[TBL] [Abstract][Full Text] [Related]
15. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
16. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
17. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
Akapirat S; Karnasuta C; Vasan S; Rerks-Ngarm S; Pitisuttithum P; Madnote S; Savadsuk H; Rittiroongrad S; Puangkaew J; Phogat S; Tartaglia J; Sinangil F; de Souza MS; Excler JL; Kim JH; Robb ML; Michael NL; Ngauy V; O'Connell RJ; Karasavvas N;
PLoS One; 2018; 13(4):e0196397. PubMed ID: 29702672
[TBL] [Abstract][Full Text] [Related]
18. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
20. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
